Chronic administration of XBD173 ameliorates cognitive deficits and neuropathology via 18 kDa translocator protein (TSPO) in a mouse model of Alzheimer disease
Arpit Kumar Pradhan, Tatjana Neumüller, Claudia Klug, Severin Fuchs, Martin Schlegel, Markus Ballmann, Katharina Johanna Tartler, Antoine Pianos, Maria Sanchez Garcia, Philippe Lière, Michaël Schumacher, Matthias Kreuzer, Rainer Rupprecht, Gerhard Rammes
This study shows that chronic XBD173 treatment improves cognitive deficits and reduces AD pathology in mice via TSPO, with TSPO being necessary for its procognitive effects.
Translational Psychiatry · Oct 27, 2023Peer-reviewedNeuroscience